Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.45 |
| ▸ | TUBB | P07437 | 3/20 | 0.45 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.45 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.45 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.45 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.45 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.45 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.45 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.45 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.45 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.45 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.45 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.45 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.45 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.45 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL723263 | 0.97 | PTGS2 (0.47) | PTGS2TUBB4ATUBBTUBA3CTUBA1B | |
| Phosphine SCHEMBL28014269 | 0.95 | PTGS2 (0.46) | PTGS2TUBB4ATUBBTUBA3CTUBA1B | |
| Hydrochloric Acid SCHEMBL4598739 | 0.83 | SNCA (0.41) | G6PDSMN1; SMN2MAPK1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL10424163 | 0.83 | LDHA (0.53) | MAPTSMN1; SMN2KMT2AABCB1KDM4E | |
| Bromide SCHEMBL9088261 | 0.83 | KDM4E (0.36) | PTGS2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL30596298 | 0.81 | LDHA (0.54) | MAPTSMN1; SMN2KMT2AABCB1KDM4E | |
| Bromide SCHEMBL29880790 | 0.80 | LDHA (0.53) | MAPTSMN1; SMN2KMT2AABCB1KDM4E | |
| Bromide SCHEMBL4260842 | 0.80 | LDHA (0.53) | MAPTSMN1; SMN2KMT2AABCB1KDM4E | |
| Hydrochloric Acid SCHEMBL5973630 | 0.79 | TSHR (0.46) | MAPK1ABCB1ALDH1A1CYP19A1SNCA | |
| Bromide SCHEMBL7436731 | 0.78 | TRAP1 (0.52) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976388-A1 | ANTIMICROBIAL SOLUTION COMPRISING A METALLIC SALT AND A SURFACTANT | CTT GROUP INC. (CA) | 2008-10-08 | — | — | EP | claimed |
| US-20080199502-A1 | Antimicrobial Solution Comprising a Metallic Salt and a Surfactant | CTT GROUP INC. (CA) | 2008-08-21 | — | — | US | claimed |
| WO-2006105669-A1 | ANTIMICROBIAL SOLUTION COMPRISING A METALLIC SALT AND A SURFACTANT | CTT GROUP INC. (CA) | 2006-10-12 | — | — | WO | claimed |
| US-20150201622-A1 | NEW ANTIMICROBIAL COMPOSITIONS AND USES THEREOF | CTT GROUP INC (CA) | 2015-07-23 | — | — | US | disclosed |
| US-20120302759-A1 | COMBRETASTATIN DERIVATIVE PREPARATION METHOD | C/O SANOFI (FR) | 2012-11-29 | — | — | US | disclosed |
| EP-1976388-A1 | ANTIMICROBIAL SOLUTION COMPRISING A METALLIC SALT AND A SURFACTANT | CTT GROUP INC. (CA) | 2008-10-08 | — | — | EP | disclosed |
| US-20080199502-A1 | Antimicrobial Solution Comprising a Metallic Salt and a Surfactant | CTT GROUP INC. (CA) | 2008-08-21 | — | — | US | disclosed |
| WO-2006105669-A1 | ANTIMICROBIAL SOLUTION COMPRISING A METALLIC SALT AND A SURFACTANT | CTT GROUP INC. (CA) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302759-A1 | COMBRETASTATIN DERIVATIVE PREPARATION METHOD | PCSK9, PIK3CA, TYMP | PTGS2 2986/4885TUBB4A 549/4885TUBB 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.